CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Rating of “Moderate Buy” by Analysts

CRISPR Therapeutics AG (NASDAQ:CRSP) has been given an average recommendation of “Moderate Buy” by the eighteen ratings firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, six have given a hold recommendation, ten have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $68.0556.

CRSP has been the subject of several analyst reports. HC Wainwright reiterated a “buy” rating and set a $80.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, July 8th. Citizens Jmp reaffirmed a “market outperform” rating and set a $80.00 target price on shares of CRISPR Therapeutics in a research note on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Friday, July 17th. The Goldman Sachs Group reiterated a “neutral” rating and set a $55.00 price target on shares of CRISPR Therapeutics in a research report on Thursday, August 6th. Finally, Evercore reissued an “outperform” rating and issued a $76.00 price target on shares of CRISPR Therapeutics in a research note on Monday, May 11th.

Insiders Place Their Bets

In related news, insider Naimish Patel sold 3,786 shares of the stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $55.62, for a total value of $210,577.32. Following the completion of the transaction, the insider owned 19,357 shares in the company, valued at $1,076,636.34. This represents a 16.36% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 5.20% of the stock is owned by insiders.

Institutional Trading of CRISPR Therapeutics

Institutional investors have recently made changes to their positions in the stock. Versant Capital Management Inc increased its stake in shares of CRISPR Therapeutics by 175.1% during the second quarter. Versant Capital Management Inc now owns 465 shares of the company’s stock valued at $25,000 after acquiring an additional 296 shares during the period. Mcguire Capital Advisors Inc. acquired a new stake in CRISPR Therapeutics in the fourth quarter worth approximately $25,000. Ramirez Asset Management Inc. acquired a new stake in CRISPR Therapeutics in the fourth quarter worth approximately $26,000. Rothschild Investment LLC boosted its stake in CRISPR Therapeutics by 836.7% during the 4th quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock valued at $29,000 after purchasing an additional 502 shares in the last quarter. Finally, Oakworth Capital Inc. bought a new position in CRISPR Therapeutics during the 4th quarter valued at $34,000. 69.20% of the stock is owned by institutional investors and hedge funds.

CRISPR Therapeutics Trading Down 2.7%

CRISPR Therapeutics stock opened at $59.23 on Thursday. The company has a quick ratio of 17.85, a current ratio of 17.85 and a debt-to-equity ratio of 0.34. The firm has a 50-day moving average price of $53.44 and a two-hundred day moving average price of $52.60. The firm has a market capitalization of $5.73 billion, a price-to-earnings ratio of -12.44 and a beta of 1.74. CRISPR Therapeutics has a 52-week low of $44.12 and a 52-week high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Tuesday, June 30th. The company reported ($0.94) EPS for the quarter. CRISPR Therapeutics had a negative return on equity of 24.39% and a negative net margin of 3,368.72%.The firm had revenue of $10.18 million during the quarter. Sell-side analysts expect that CRISPR Therapeutics will post -4.47 earnings per share for the current year.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent ?-thalassemia in collaboration with Vertex Pharmaceuticals.